Details of the Drug Combinations

General Information of This Drug (ID: DM602WT)

• Drug Name: Idelalisib (DM602WT)
• Synonyms: Idelalisib; 870281-82-6; CAL-101; Zydelig; GS-1101; CAL101; CAL 101; (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; UNII-YG57I8T5M0; CAL-101 (Idelalisib, GS-1101); YG57I8T5M0; CHEMBL2216870; CHEBI:82701; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; AK145603; Idelalisib; CAL-101; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE

Indication

Chronic lymphocytic leukaemia; ICD 11: 2A82.0; Status: Approved [1]; Small lymphocytic lymphoma; ICD 11: 2A82.0; Status: Approved [2]; Follicular lymphoma; ICD 11: 2A80; Status: Investigative [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

6 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Idelalisib + Acalabrutinib	DCXVNC5	Acalabrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[3]
Idelalisib + Mitomycin	DCL5A6G	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[3]
Idelalisib + Idarubicin	DCP33A2	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]
Idelalisib + PF-562271	DCQVE76	PF-562271	Diffuse large B cell lymphoma (Cell Line: TMD8)	[3]
Idelalisib + Ibrutinib	DC86FWO	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[3]
Idelalisib + Ruxolitinib	DCCML2I	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[4]

9 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Idelalisib + Fludarabine	DCFC49D	Fludarabine	Indolent Non-Hodgkin's Lymphoma	[5]
Idelalisib + GS-9973	DCFV208	GS-9973	Chronic Lymphocytic Leukemia	[6]
Idelalisib + Lenalidomide	DCHP9FQ	Lenalidomide	Recurrent Follicular Lymphoma	[7]
Idelalisib + Everolimus	DCN0GD0	Everolimus	Indolent Non-Hodgkin's Lymphoma	[5]
Idelalisib + Chlorambucil	DCUX3GM	Chlorambucil	Indolent Non-Hodgkin's Lymphoma	[5]
Idelalisib + GS-4059	DCIMVSI	GS-4059	B-cell Malignancies	[8]
Idelalisib + Rocilinostat	DCXCW67	Rocilinostat	Recurrent Chronic Lymphoid Leukemia	[9]
Ruxolitinib + Idelalisib	DC1P6X3	Ruxolitinib	Myelofibrosis	[10]
Idelalisib + GS-4059	DCM20AR	GS-4059	Chronic Lymphocytic Leukemia	[11]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6741).
• [2] Idelalisib FDA Label
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [5] ClinicalTrials.gov (NCT01088048) Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
• [6] ClinicalTrials.gov (NCT01796470) Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
• [7] ClinicalTrials.gov (NCT01644799) Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
• [8] ClinicalTrials.gov (NCT02457598) Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
• [9] ClinicalTrials.gov (NCT02787369) ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
• [10] ClinicalTrials.gov (NCT02436135) Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease
• [11] ClinicalTrials.gov (NCT02968563) Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)